Post-earnings recap
Reported
Mon, May 12, 2025
EPS actual
$-0.52
EPS est.
$-0.66
EPS surprise
+20.97%
1-day move
+6.43%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Immunome's earnings report showed a better-than-expected EPS, which contributed to a positive stock reaction, with shares rising 6.43%. The company did not disclose revenue figures or future guidance, leaving investors to focus on the positive EPS surprise and management's optimistic tone about ongoing projects. This could indicate potential for growth if their pipeline progresses as planned.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.52 | N/A | +20.97% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding their ongoing projects. They emphasized the importance of their research efforts while refraining from giving specific financial guidance.
Management highlighted the progress in their pipeline development.
They expressed confidence in future clinical trials, though no specific guidance was provided.